Analysts See $-0.68 EPS for BeyondSpring Inc. (BYSI)

August 12, 2018 - By Michele Cranor

Analysts expect BeyondSpring Inc. (NASDAQ:BYSI) to report $-0.68 EPS on August, 20.They anticipate $0.29 EPS change or 74.36 % from last quarter’s $-0.39 EPS. After having $-0.61 EPS previously, BeyondSpring Inc.’s analysts see 11.48 % EPS growth. The stock decreased 1.67% or $0.4 during the last trading session, reaching $23.6. About 16,372 shares traded or 110.44% up from the average. BeyondSpring Inc. (NASDAQ:BYSI) has risen 0.37% since August 13, 2017 and is uptrending. It has underperformed by 12.20% the S&P500.

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company has market cap of $546.93 million. The firm is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab. It currently has negative earnings.

Another recent and important BeyondSpring Inc. (NASDAQ:BYSI) news was published by Nasdaq.com which published an article titled: “BeyondSpring Appoints Richard J. Daly as Chief Operating Officer to Lead the Transition to Commercialization” on August 01, 2018.

BeyondSpring Inc. (NASDAQ:BYSI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.